A Phase Ia/Ib, Open-Label, Multi-Center, Study of the Safety, Tolerability and Primary Efficacy of IBI321 in Patients With Advanced Solid Tumors
Latest Information Update: 03 Mar 2023
At a glance
- Drugs IBI 321 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Innovent Biologics
- 27 Feb 2023 Status changed from active, no longer recruiting to completed.
- 10 Oct 2022 Status changed from recruiting to active, no longer recruiting.
- 26 Jul 2021 Status changed from not yet recruiting to recruiting, according to an Innovent Biologics media release.